Your browser doesn't support javascript.
loading
Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry.
Cao, Thong Huy; Tay, Wan Ting; Jones, Donald J L; Cleland, John G F; Tromp, Jasper; Emmens, Johanna Elisabeth; Teng, Tiew-Hwa Katherine; Chandramouli, Chanchal; Slingsby, Oliver Charles; Anker, Stefan D; Dickstein, Kenneth; Filippatos, Gerasimos; Lang, Chim C; Metra, Marco; Ponikowski, Piotr; Samani, Nilesh J; Van Veldhuisen, Dirk J; Zannad, Faiez; Anand, Inder S; Lam, Carolyn S P; Voors, Adriaan A; Ng, Leong L.
Afiliação
  • Cao TH; Department of Cardiovascular Sciences, College of Life Sciences, University of Leicester, Leicester, UK.
  • Tay WT; National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK.
  • Jones DJL; Leicester van Geest Multi-OMICS facility, University of Leicester, Leicester, UK.
  • Cleland JGF; National Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore.
  • Tromp J; Department of Cardiovascular Sciences, College of Life Sciences, University of Leicester, Leicester, UK.
  • Emmens JE; Leicester van Geest Multi-OMICS facility, University of Leicester, Leicester, UK.
  • Teng TK; Leicester Cancer Research Centre, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, University of Leicester, Leicester, UK.
  • Chandramouli C; British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  • Slingsby OC; National Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore.
  • Anker SD; Saw Swee Hock School of Public Health, National University of Singapore and the National University Health System, Singapore, Singapore.
  • Dickstein K; Department of Cardiology, University of Groningen, Groningen, The Netherlands.
  • Filippatos G; National Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore.
  • Lang CC; National Heart Centre Singapore and Duke-National University of Singapore, Singapore, Singapore.
  • Metra M; Department of Cardiovascular Sciences, College of Life Sciences, University of Leicester, Leicester, UK.
  • Ponikowski P; National Institute for Health and Care Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK.
  • Samani NJ; Leicester van Geest Multi-OMICS facility, University of Leicester, Leicester, UK.
  • Van Veldhuisen DJ; Division of Cardiology and Metabolism, Department of Cardiology (CVK), and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Zannad F; University of Bergen, Stavanger University Hospital, Stavanger, Norway.
  • Anand IS; Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Lam CSP; Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
  • Voors AA; Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
  • Ng LL; Department of Heart Diseases, Wroclaw Medical University and Cardiology Department, Military Hospital, Wroclaw, Poland.
Eur J Heart Fail ; 2024 Aug 09.
Article em En | MEDLINE | ID: mdl-39119882
ABSTRACT

AIMS:

We investigated the prevalence, clinical characteristics, and prognosis of patients with heart failure (HF) with improved ejection fraction (HFimpEF). METHODS AND

RESULTS:

We used data from BIOSTAT-CHF including patients with a left ventricular ejection fraction (LVEF) ≤40% at baseline who had LVEF re-assessed at 9 months. HFimpEF was defined as a LVEF >40% and a LVEF ≥10% increase from baseline at 9 months. We validated findings in the ASIAN-HF registry. The primary outcome was a composite of time to HF rehospitalization or all-cause mortality. In BIOSTAT-CHF, about 20% of patients developed HFimpEF, that was associated with a lower primary event rate of all-cause mortality (hazard ratio [HR] 0.52, 95% confidence interval [CI] 0.28-0.97, p = 0.040) and the composite endpoint (HR 0.46, 95% CI 0.30-0.70, p < 0.001) compared with patients who remained in persistent HF with reduced ejection fraction (HFrEF). The findings were similar in the ASIAN-HF (HR 0.40, 95% CI 0.18-0.89, p = 0.024, and HR 0.29, 95% CI 0.17-0.48, p < 0.001). Five independently common predictors for HFimpEF in both BIOSTAT-CHF and ASIAN-HF were female sex, absence of ischaemic heart disease, higher LVEF, smaller left ventricular end-diastolic and end-systolic diameter at baseline. A predictive model combining only five predictors (absence of ischaemic heart disease and left bundle branch block, smaller left ventricular end-systolic and left atrial diameter, and higher platelet count) for HFimpEF in the BIOSTAT-CHF achieved an area under the curve of 0.772 and 0.688 in the ASIAN-HF (due to missing left atrial diameter and platelet count).

CONCLUSIONS:

Approximately 20-30% of patients with HFrEF improved to HFimpEF within 1 year with better clinical outcomes. In addition, the predictive model with clinical predictors could more accurately predict HFimpEF in patients with HFrEF.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Eur J Heart Fail Assunto da revista: CARDIOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Eur J Heart Fail Assunto da revista: CARDIOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido